

pevion
B I O T E C H

2006
annual report

pevion
B I O T E C H

Pevion Biotech Ltd.
Rehhagstrasse 79
CH-3018 Bern
Switzerland
Phone +41 31 980 62 03
Fax +41 31 980 66 18
info@pevion.com
www.pevion.com

INDEX

LETTER FROM THE CEO3

HIGHLIGHTS 20064

COMPANY PROFILE6

VIROSOME-BASED TECHNOLOGY9

LEAD PROJECTS 200611

INTELLECTUAL PROPERTY15

LETTER FROM THE CEO

2006 ANNUAL REPORT

DEAR SHAREHOLDER

Pevion Biotech has dedicated its resources to the discovery and development of therapeutic and prophylactic virosome-based vaccines. As the leading company in the field of virosomes, Pevion is constantly advancing its virosome technology and strengthening the necessary IP portfolio in order to optimize the protection of the generated products for a long period of time.

The last twelve months have been very exciting for Pevion Biotech. We have progressed with two of our lead vaccine candidates into clinical development and with one project into preclinical development. Altogether, at the end of 2006 Pevion Biotech had three products in clinical development: a breast cancer vaccine, a HCV vaccine and a malaria vaccine.

The clinical trial Phase I with our PeviPRO™ breast cancer vaccine candidate PEV6A started on September 25, 2006 at the University Hospital (AKH) in Vienna in collaboration with Bio Life Science. The study comprises 20 metastatic breast cancer patients, and the primary endpoints include the evaluation of safety, tolerability and the immunogenicity of the vaccine. In the course of the study each patient receives three vaccinations followed by a close monitoring. Our active immunization approach may help to fight the disease for a longer time period compared to the present passive immunization standard treatment using monoclonal antibodies.

The clinical trial Phase I study with our PeviTER™ HCV vaccine PEV2A,B started on December 18, 2006 at the University Hospital in Lausanne. The study has enrolled 30 healthy volunteers and also assesses safety, tolerability and immunogenicity. Our new modular and therapeutic type of HCV vaccine is based on the PeviTER™ technology. It utilizes the effect to induce a specific CTL response together with a supportive T helper cell response. An appropriate cellular immune response seems to be crucial in overcoming an HCV infection.

Pevion Biotech is in line with the expectations for 2006 and is transforming itself more and more into a clinical company, as projects in the pipeline constantly move from preclinical to clinical status. Again, the company has proven its strong capability to further develop a pipeline of innovative virosome-based vaccine products.

The strong product pipeline, the significant scientific advancements, the strong patent portfolio and a highly motivated team have strengthened Pevion Biotech's developmental potency, paving the way to start a second financial placement and ensuring that the company was well prepared for the due diligences in Q4 2006 by potential investors. So, at the end of the year Pevion Biotech was well positioned for the financing round in 2007. I am looking forward to the even more exciting year 2007.

Sincerely,



Peter Klein
CEO Pevion Biotech AG

HIGHLIGHTS 2006

2006 ANNUAL REPORT

→ Start of Phase I of Pevion Biotech's breast cancer vaccine

In September 2006 Pevion Biotech announced the start of Phase I clinical testing of its virosome-based breast cancer vaccine. The multivalent vaccine will be tested for its safety and immunogenicity in patients overexpressing the HER-2/neu oncoprotein.

→ Start of Phase I of Pevion Biotech's hepatitis C vaccine

In December 2006 Pevion Biotech announced the start of Phase I clinical testing of its virosome-based hepatitis C virus (HCV) vaccine. The therapeutic HCV vaccine is based on Pevion Biotech's proprietary PeviPRO™ and PeviTER™ technologies and will be tested for its safety and immunogenicity.

→ Positive final Phase I results for Pevion Biotech's malaria vaccine and completion of Phase IIa

In March 2006 Pevion Biotech announced that two components of its prophylactic malaria vaccine PEV3A had successfully finished a Phase I clinical trial. A final report confirmed that vaccination at all dose levels was well tolerated in all subjects and generated a long lasting and specific antibody immune response. The positive results allowed a rational design for the Phase IIa study in Oxford, which was completed in Q4 2006. Data are not yet available.

→ Improvement of virosome-based technology

To further improve virosome technology, Pevion Biotech is constantly seeking new challenges beyond the validated standard formulations. In this context Pevion Biotech currently has developed a novel and unique type of virosome that can be lyophilized without loss of activity and immunogenicity but has extended storage characteristics. This achievement will be favorable for manufacturing and worldwide logistic issues.

→ Preparation for Due Diligence in 2007

The second half of 2006 was marked by the upcoming finance round in early 2007. Pevion Biotech made a concerted effort to be well under way for the preparation of all needed documents and presentations.

→ License agreement with Mymetics

Mymetics (Nyon, Switzerland) has signed an exclusive license for the use of Pevion Biotech's virosome-based technology platform for the development and production of an HIV vaccine.

→ New patents

Pevion Biotech extended its portfolio in 2006 by filing two additional patent applications.

COMPANY PROFILE

2006 ANNUAL REPORT


Pevion Biotech is a Swiss developing company active in one of the fastest growing markets in the pharmaceutical industry, the vaccine field. Since its foundation as an industrial spin-off in 2002 the company has been focusing on the preclinical and clinical development of vaccines to treat and prevent infectious and chronic diseases. The target indications represent major medical needs, including breast cancer, hepatitis C, candidiasis, DiTe, RSV and malaria.

Pevion Biotech applies a validated technology that has already been approved by regulatory authorities. Two vaccines with this technology are on the market and are being produced in large quantities (> 30 million doses). Additionally, the established development and manufacturing process allows an accelerated development and GMP manufacturing in accordance with industrial standards, resulting in rapid transition of the preclinical vaccine candidates to clinical products.

The company currently has three of its products in clinical testing. The malaria vaccine, the most advanced one, is in clinical Phase IIa, whereas a breast cancer vaccine and the hepatitis C vaccine are in clinical Phase I. The latter represents a novel generation of therapeutic vaccines. It can be used to treat diseases, specifically chronic diseases including cancer and chronic infectious diseases.

Pevion Biotech is a dedicated biopharmaceutical company with an experienced executive team and a renowned scientific advisory board. As of the end of 2006 the company had a staff of 19 employees, nine of whom have a PhD degree.

Pevion Biotech has the most complete patent portfolio regarding virosomes (10 patent families and over 90 granted national patents), covering all aspects and applications of the virosome technology platforms. Additionally, the company has 7 patent families covering the antigens used in its products. The company is also the registered owner of a number of trademarks.



Pevion Biotech's product pipeline as of January 1st, 2007

MANAGEMENT**Peter Klein, Chief Executive Officer (CEO)**

Peter Klein was head of regulatory affairs at Berna Biotech prior to his employment at Pevion Biotech. His previous professional activities include 8 years of experience as head of the registration department at the Swiss Drug Regulatory Authority SWISSMEDIC, 10 years in private consulting to the pharmaceutical industry (Europe, USA and Japan) and 4 years of employment in medium-sized pharmaceutical companies in clinical development and registration of pharmaceutical products. Peter Klein studied biology at the University of Basel, Switzerland.

Dr. Thomas Stauffer, Chief Operating Officer (COO)

Thomas Stauffer joined Pevion Biotech in 2002. Prior to his employment at Pevion Biotech, he served as an IP consultant for small and midsize biotechnology companies and built and managed a department for IP services at the Swiss Federal Institute of Intellectual Property. Prior to that, Thomas Stauffer worked for 3 years at Duke University Medical Center (Durham, NC). Thomas Stauffer received his degree from the Swiss Federal Institute of Technology in Zurich, Switzerland.

Dr. Rinaldo Zurbriggen, Chief Scientific Officer (CSO)

Rinaldo Zurbriggen is co-founder of Pevion Biotech. Prior to joining Pevion Biotech, Rinaldo Zurbriggen was head of the virus research department at Berna Biotech, where he was responsible for the development of virosome-based vaccines from 1996 on. During this period his department enabled Berna Biotech to register the first virosome-based vaccine (Epaxal) in Europe. Rinaldo Zurbriggen is a leading expert for virosomes and has published more than 30 papers in peer-reviewed scientific journals in this field. Rinaldo Zurbriggen earned his degree at the University of Fribourg, Switzerland.

BOARD OF DIRECTORS**Peter Grogg, PhD, Chairman of the Board, President Bachem Holding AG**

Peter Grogg founded Bachem in 1971 and is chairman of the board of directors of the Bachem Group. He holds main seats on other boards: Dottikon ES Holding AG and is management board member of the Swiss Association for the Chemical Industry and of the Basel Chamber of Commerce. He was awarded the academic degree of Doctor of Philosophy honoris causa by the University of Basel, Switzerland.

Kuno Sommer, PhD, Vice-Chair of the Board, CBO Crucell

Kuno Sommer studied business administration at the University of Basel. Before 1990 he held various positions with Roche AG Vitamin Marketing. From 1990 to 1994 he was head of the North American branch of the Roche Animal Feed and Health Division, from 1995, manager of global marketing for the Vitamin and Speciality Chemicals Division in Basel, CEO of Givaudan-Roure in Geneva and member of the executive committee of Roche AG in 1998/99.

Jaap Goudsmit, PhD, Member of the Board, CSO Crucell

Jaap Goudsmit is responsible for Crucell's R&D activities. Prior to joining Crucell, Dr Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, and was chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Dr. Goudsmit has also taught at the National Institutes of Health and New York University.

He was founding Chairman of the Scientific Advisory Committee of the International AIDS Vaccine Initiative and the founding co-chair of the European Vaccine Effort against AIDS (EuroVac). In 2003 he was appointed chairman of the board of the AIDS Foundation East-West.

Daniel Erne, PhD, Member of the Board, CTO Bachem Holding AG

Daniel Erne joined Bachem AG in 1987 as head of quality control. Since 1997 he has been a member of the corporate executive Committee of the Bachem Group and responsible for quality assurance and regulatory affairs. He studied chemistry at the Swiss Federal Institute of Technology in Zurich (ETHZ) and then became a research fellow at the University of Utah, Salt Lake City and at ETHZ before joining Bachem AG.

SCIENTIFIC ADVISORY BOARD

Besides its internal scientists, Pevion Biotech has established a scientific advisory board comprised of highly skilled experts, including academic researchers in immunology, biochemistry as well as clinical oncology.

Prof. Dr. Albert Osterhaus

Professor Osterhaus is a world renowned specialist for infectious diseases and vaccines. He studied and completed his doctorate at the University of Utrecht and held various positions at the National Institute of Public Health and Environment (RIVM) in Bilthoven, the Netherlands. He was directly involved in the establishment of three companies. Among other positions, Professor Osterhaus currently holds the position of Professor of Virology, Erasmus University Hospital, Rotterdam and is member of a number of WHO committees.

Prof. Dr. Antonio Lanzavecchia

Professor Antonio Lanzavecchia is a world renowned immunologist with a research focus on different aspects of cellular immunology: antigen processing and presentation, dendritic cell biology, lymphocyte activation and lymphocyte traffic. He studied at the University of Pavia and then specialized in pediatrics and infectious diseases. He was a member of the staff at the Basel Institute for Immunology and became director of the Institute for Research in Biomedicine in Bellinzona and professor at the University of Siena. He was awarded the EMBO Medal in 1988 and the Cloëtta Prize in 1999.

Prof. Dr. Alan Gewirtz

The laboratory of Professor Alan Gewirtz focuses on the cell biology of normal and malignant human hematopoiesis. He began his studies at Colgate University and became assistant professor at Temple University School of Medicine. He then was appointed director of the Clinical Hematology Laboratory at Temple University Hospital as well as associate professor at the University of Pennsylvania, where he currently heads the Hematologic Malignancies Program.

Prof. Dr. Josef Brunner

Professor Josef Brunner's most important research topics are the development of new photochemical marking methods to examine complex systems, the fusion of biological membranes as well as the role of lipids and lipid metabolites in signal transduction. He studied at Technical College (HTL) in Burgdorf, Switzerland and ETH Zurich, where he was awarded the ETH Silver Medal. After a postdoctorate at the Department of Molecular Biophysics and Biochemistry, Yale University, he headed his own research group at ETH Zurich.

VIROSOME-BASED TECHNOLOGY

2006 ANNUAL REPORT


NEXT GENERATION VIROSOME-BASED TECHNOLOGY PLATFORMS

The first virosome-based vaccine was marketed in 1997: Inflexal® V, a vaccine against influenza, followed by Epaxal®, a vaccine against hepatitis A. Both have been registered in Europe and other countries including Canada and Australia. They are successfully marketed by Crucell.


In the past years Pevion Biotech was able to gradually improve the technology in terms of versatility, manufacturing and storage conditions. Today, the virosome-based technology is well established with a cGMP certification and a fully scalable production process. It is one of only three regulatory approved adjuvants. Due to its extensive clinical and technological know-how, Pevion Biotech is able to promote its vaccine candidates through an effective product development process with minimized development risks and a rapid registration process.

BASICS OF VIROSOME-BASED TECHNOLOGY

Virosomes are characterized by their high versatility. They function as both carrier platforms and adjuvants. Virosomes consist of reconstituted empty influenza virus envelopes devoid of the nucleocapsid, including the genetic material of the source virus.



Influenza virus



Virosome

Virosomes are not able to replicate but are pure fusion-active vesicles. In contrast to liposomes, virosomes contain functional viral envelope glycoproteins: influenza virus hemagglutinin and neuraminidase intercalated in the phospholipid bilayer membrane.


The unique properties of virosomes partially relate to the presence of these glycoproteins. They not only confer structural stability and homogeneity to virosome formulations, but they significantly contribute to the immunological properties of virosomes, which are clearly distinct from other liposomal and proteoliposomal carrier systems. These proteins enable the virosome membranes to fuse with cells of the immune system and thus deliver their contents – the specific antigens – directly to their target cells, eliciting a specific first-class immune response even with weak-immunogenic antigens. Once they have delivered the antigens, the virosomes are completely metabolized. Conventional adjuvants like aluminum can not be degraded by the body.

NEW IN 2006: LYOPHILIZABLE VIROSOMES

Pevion Biotech is constantly seeking to optimize its vaccine candidates. Working with synthetic peptides or recombinant proteins often has the disadvantage of limited stability. In addition, vaccines are temporarily exposed to elevated temperatures that cause losses in vaccine efficacy. Lyophilization (freeze-drying) is a process that is especially useful for enhancing stability for long-term storage of biological materials such as

proteins and vaccines, and it can make refrigerated storage obsolete for normally temperature-sensitive materials. However, conventional "first generation" virosomes cannot be lyophilized without loss of immunogenicity, particle size homogeneity and the functional activity of the influenza HA. Therefore, we have developed a new generation of virosomes which are able to induce strong immune responses, display a good antigen encapsulation rate and improved storage and stability properties. This is combined with a simple and fast preparation method that offers a great flexibility in combining several specific antigens of choice while retaining the adjuvant properties and the excellent safety profile.

Pevion Biotech's new generation of virosomes can be lyophilized, but they retain all functional and structural properties of virosomes. This feature allows long-term storage of virosomes without interference with its functions. If desired, antigens can be part of the lyophilisate, or the lyophilisate can be reconstituted with the antigens of choice at an appropriate concentration. They also offer the advantage that antigen can enter the lumen of the virosome during the reconstitution process. Therefore, TIRIVs offer a flexible antigen delivery vehicle with long-term storage capability inducing strong cellular and/or humoral immune responses. The lyophilizable virosomes are patented by Pevion Biotech.



Lyophilization of virosomes: Virosomes form in a special solution (1). Dried virosomes can be stored for longer times at room temperature (2). They may be reconstituted in aqueous solution right at the time and with the selected antigen of choice when needed (3). The virosome-based vaccine is ready for administration by health care professionals (4).

LEAD PROJECTS 2006

2006 ANNUAL REPORT

Development pipeline of Pevion Biotech

Pevion Biotech's product pipeline consists of vaccines to treat or prevent infectious diseases and cancer, representing high unmet medical needs:

- Breast cancer
- Hepatitis C (HCV)
- Booster Diphtheria / tetanus (DiTe) vaccine
- Candidiasis
- Respiratory Syncytial Virus (RSV)
- Malaria

Additional products are in preclinical development.

BREAST CANCER VACCINE IN CLINICAL PHASE I

PeviPRO™ breast cancer vaccine I

Pevion Biotech has designed a multivalent breast cancer vaccine for patients in whom the HER-2/neu oncoprotein is overexpressed. In collaboration with Bio Life Science, a biotech company located in Vienna, the protein sequence of the extracellular domain (ECD) of the human Her-2/neu protein was scanned by computer-aided prediction, and three peptides were selected for further investigation. These three synthetic Her-2/neu antigen-derived peptides are presented to the immune system in multiple copies on the surface of virosomes based on the PeviPRO™ technology platform.

Start of clinical Phase I

The successful results of the preclinical studies resulted in the start of a Phase I clinical trial in September 2006 in Vienna. The primary aim of the study is to examine the safety and tolerability of the synthetic vaccine. Secondary objectives include assessments of the vaccine's immunogenicity. In the course of the study each subject will receive five vaccinations and will then be closely monitored. The study is scheduled for completion by mid-2007.

Advantages of a breast cancer vaccine

Breast cancer is one of the most common cancer types among woman. More than 1.2 million women worldwide are affected by breast cancer, irrespective of age and ethnicity. Some breast cancer patients in whom the Her-2/neu protein is strongly overexpressed can be treated with an immunotherapy Herceptin® (Trastuzumab). The therapy with human-approved monoclonal antibodies is a passive immunization of the patient, targeting a disease-related molecule, but it must be repeated weekly or monthly and is very cost intensive.

Pevion Biotech's approach is also based on the Her-2/neu tumor antigen, but the antibodies will be induced by a cancer vaccine. Through an active immunization with the virosome-based vaccine, Pevion Biotech expects a greater longevity, fewer injections, lower costs, a therapeutic treatment of a broader patient group also with lower Her-2/neu expressing tumors,

treatment for preventing a relapse of the tumor and even a prophylactic treatment for healthy persons with a high risk of cancer.

HCV: THERAPEUTIC VACCINE IN CLINICAL PHASE I

Start of clinical Phase I

Pevion Biotech has designed a therapeutic vaccine to treat patients who suffer from chronic hepatitis C virus infection. The vaccine is based on a combination of the PeviPRO™ and PeviTER™ platforms using synthetic peptide antigens from the hepatitis C virus. This virosome-based technological combination in a single product represents a new generation of modular therapeutic vaccines. In 2006 the preparation of a clinical trial was ongoing and resulted in the start of a Phase I clinical trial in December 2006. The primary goal of the study is to examine the safety and tolerability of the synthetic vaccine. Secondary objectives include assessments of the vaccine's immunogenicity. In the course of the study each subject will receive multiple injections. During the clinical trial the volunteers will be closely monitored. The study is scheduled for completion by end of 2007.

Need of a HCV vaccine

Hepatitis C is one of the most common blood-borne infections. It is considered a serious health problem affecting 200 million people worldwide. 85% of infected persons cannot eliminate the virus and about 70% develop chronic hepatitis. Many of the chronically infected are at risk of developing liver cirrhosis (20%) and/or liver cancer (hepatocellular carcinoma, HCC) (1-5% per year). So far, combination therapy with interferon and ribavirin is the only treatment for chronic hepatitis C. Unfortunately, up to 60% of all HCV-infected patients do not experience significant long-term benefits from this therapy. Despite great need, no vaccine is yet available.

First PeviTER™ vaccine in combination with PeviPRO™

Pevion Biotech's HCV vaccine is the first vaccine candidate which is based on the combination of the two virosome-based technologies. In-depth research in recent years has shown that to evoke the full biological potential of the specific CD8+ T cell responses, a support by CD4+ T helper cells is needed. This effect utilizes Pevion Biotech's virosome-based platform by offering the opportunity to induce a specific CD8+ T cell response together with a CD4+ immune response. This represents a new generation of a highly effective therapeutic vaccine, which stimulates both – the cellular and the humoral immune response.

FURTHER PRODUCTS IN DEVELOPMENT

Booster DiTe vaccine

Diphtheria and Tetanus are serious infectious diseases. Even with treatment, both diseases cause high mortality rates unless intense supportive treatment is rapidly initiated. The very best therapy is disease prevention by prophylactic vaccination, a strategy that is promoted worldwide by national and international health authorities. The immunization coverage rate is 78% of the world population and keeps increasing. Ideally, each child should receive five shots of the combined diphtheria and tetanus (DiTe) vaccine within the first seven years of life, and subsequent booster immunizations are recommended for adults every ten years. Vaccines against diphtheria and tetanus were among the first prophylactic immunizations to be developed and their design, so-called toxoids adjuvanted with aluminum salts, has remained the same since the 1940s.

The existing DiTe vaccines provide excellent protection at low cost. However, immunization with these vaccines, in particular the booster immunizations of adults, are frequently accompanied by painful local reactions at the injection site and general symptoms like headache, fatigue and fever. The decreasing acceptance of side effects together with poor disease awareness is the major threat to compliance of the population with recommended vaccination schedules in industrialized countries. A reliable, efficient and safer booster vaccine meets a public health need and represents a business opportunity at the same time.

Pevion Biotech aims to develop a DiTe vaccine based on its proprietary PeviPRO™ technology platform. The preclinical results suggest that a virosome-based DiTe vaccine containing a significantly reduced toxoid dose can induce an adequate and fully protective immunity in humans.

PeviPRO™ candida vaccine

Vaginal candida infections have emerged as a significant medical problem during the last few decades. Candida species usually reside as commensal organisms as part of an individual's normal microflora and can be detected in approximately 50% of the population in this form. However, if the balance of the normal flora is disrupted, Candida species become pathogenic. Several drugs, especially OTC-products (over the counter), are available for treatment of fungal infections, but given the continuing increase in the incidence of infections together with the antifungal drug resistance, Candida infections pose a significant public health problem.

The majority of cases of Candida vulvovaginitis occur in about 70% of premenopausal women at least once during their reproductive life. About 30% of women experience recurrent episodes of the infection during their childbearing years. About 5% of women with a primary episode subsequently experience chronic vulvovaginal Candida infections with at least 3-4 episodes within one year.

There is a need of new antifungal treatment with a greater potential to prevent vulvovaginal or oral infections, especially chronic and/or recurrent infections, which pose serious problems for the overall health of the patients.

Pevion Biotech, together with ISS, Rome, identified an optimal antigen for a vaccine against candidiasis. In 2006 the project finished the conceptual phase and entered preclinical development. A major milestone is the manufacturing of the antigen in GMP grade.

PeviPRO™ RSV vaccine

Although respiratory syncytial virus (RSV) is traditionally regarded as a pediatric illness, it also causes pulmonary disease in the elderly, particularly those with underlying heart and lung disease and immunocompromised bone marrow recipients. Even though there is a tremendous need, no vaccine is yet available. RSV vaccine development is hampered by a number of obstacles, especially the risk of inducing enhanced illness. This has been observed after vaccination with formalin-inactivated RSV (FI-RSV) known as Lot100. 80% of the vaccinees needed hospitalization after natural infection with RSV in contrast to only 5% of the children receiving the control vaccine. Tragically, two of the vaccinees died from the infection. Disease enhancement was identified as immune pathology characterized by lung infiltration with lymphocytes and granulocytes (particularly eosinophils). The immune-pathology is induced by factors associated with the virus-inactivation as well as the adjuvant. Therefore, further specification and focusing of the vaccine towards certain parts of the virus and combination

with a suitable carrier are necessary to prevent the induction of the fatal reactions to subsequent infection with RSV.

Pevion Biotech is developing its prophylactic RSV vaccine based on its proprietary PeviPRO™ technology platform. In 2006 the RSV vaccine was further developed and will reach preclinical development in 2007.

PeviPRO™ malaria vaccine

Malaria remains one of the world's greatest public health challenges. It is one of the biggest killers among communicable diseases today. An estimated 40% of the world's population are at risk of malaria with 500 million cases annually, resulting in 1-2 million deaths each year, mostly young children and pregnant women in sub-Saharan Africa. The introduction of widespread resistance to anti-malaria drugs such as chloroquine and the difficulty of controlling the mosquito vector have hampered the control of the disease. As yet no vaccine is available.

The malaria parasite *Plasmodium falciparum* has a complex life cycle involving three stages in the human body. Pevion Biotech is therefore focusing on a multicomponent (multivalent) malaria vaccine: each component targets another antigen specific to a defined development stage. Pevion Biotech uses its well-established virosome technology platform PeviPRO™ for the delivery of the newly developed peptide antigens into the human body. In subsequent steps the company has developed the vaccine formulations to clinical development. One significant 2006 milestone was the positive final report of the Phase I clinical trial in which two components of the prophylactic malaria vaccine PEV3A were successfully tested. The clinical results showed that both vaccine components influence the growth of the parasite in vivo. In 2006 a Phase IIa clinical trial was also completed. The results of the Phase IIa study confirmed the results of the Phase I study with regard to good tolerability, and a specific immune response generated by the malaria vaccine components. The effects shown in the Phase IIa study also validated that the peptide antigens have the right conformation and should be included in a final multicomponent malaria vaccine. Pevion Biotech will further promote its malaria vaccine in a planned Phase Ib study in 2007.

INTELLECTUAL PROPERTY

2006 ANNUAL REPORT

Pevion Biotech's IP Portfolio: Two additional applications in 2006

Pevion Biotech's goal is to have patents protecting all the various aspects of its virosome technology platform as well as patents protecting the product-specific aspects of every individual product candidate in development. A strong patent position is crucial for the successful licensing of products in development. Therefore, Pevion Biotech is pursuing a very restrictive patent application strategy.

Pevion Biotech therefore extended its portfolio in 2006 by two additional patent applications which cover specific aspects of its products as well as the technology. In total, Pevion Biotech's patent portfolio has more than 18 patent families, of which 12 families cover the specific aspects of the virosome technology.



Pevion Biotech Ltd.
Rehhagstrasse 79
CH-3018 Bern
Switzerland
Phone +41 31 980 62 03
Fax +41 31 980 66 18
info@pevion.com
www.pevion.com